The U.S. Food and Drug Administration (FDA) on Wednesday approved the world’s first successful treatment for the Ebola virus, a major step against one of the world’s deadliest pathogen.

The FDA gave its formal blessing to Inmazeb, a mixture of three monoclonal antibodies produced by the American pharmaceutical company Regeneron, after a trial among 382 adult and pediatric patients in the Democratic Republic of the Congo.

The new treatment is a breakthrough, but not one that completely eliminates the threat of a virus that can kill as many as nine in ten of those who contract it if they are not treated….

Read the full The Hill article